Analyst Ratings for Intellia Therapeutics (NTLA)
NTLA Rating Summary
NTLA Price Target Summary
- Highest: $106.00 (Brookline Capital Markets)
- Lowest: $5.00 (JPMorgan)
- Average: $25.71
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$25.71 (+126%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
Avg. $ Target:
$25.71 (+126%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/16/2026 | Wolfe Research | Andy Chen | Downgrade | Underperform (Peerperform) |
9.00 (N/A) |
13.30 (11.38) |
-14.44% | Details |
| 3/4/2026 | Jones Trading | Debanjana Chatterjee | Upgrade | Buy (Hold) |
29.00 (N/A) |
13.60 (11.38) |
-16.32% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
